Sunshine Biopharma Inc SBFM
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Sunshine Biopharma Inc is a pharmaceutical company operating in Canada. It focuses on the research, development, and commercialization of proprietary drugs for the treatment of various forms of cancer. The key product of the company is Adva-27a, a small molecule that destroys multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells and uterine sarcoma cells. The company also sells several prescription generic drugs under its own brand SBI such as SBI-Anastrozole for treatment of Breast Cancer, SBI-Letrozole for treatment of Breast Cancer, SBI-Bicalutamide for treatment of Prostate Cancer and SBI-Finasteride for treatment of benign prostatic hyperplasia.
Pointe-Claire, QC, H9R 0A5